Tetrodotoxin - Dogwood therapeutics
Alternative Names: 9401-TTX; Halneuron; Tectin; Tetrodin; TocudinLatest Information Update: 29 Jan 2025
Price :
$50 *
At a glance
- Originator Beijing Medical University; WEX Pharmaceuticals
- Class Anaesthetics; Analgesics; Antiarrhythmics; Drug withdrawal therapies; Quinazolines
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Cancer pain
- Phase II Neuropathic pain; Pain; Peripheral nervous system diseases
- Suspended Opioid-related disorders
- No development reported Anaesthesia
Most Recent Events
- 21 Jan 2025 Dogwood Therapeutics plans a phase IIb HALT-CINP trial for Neuropathic pain (Chemotherapy-induced), in first quarter of 2025
- 07 Oct 2024 Tetrodotoxin receives Fast Track designation for Neuropathic pain [Parenteral,Injection] (Chemotherapy-induced) in USA
- 01 Mar 2024 WEX Pharmaceuticals completes a phase II trial in Pain (In volunteers, In adults) in Netherlands (SC) (ISRCTN78737401)